Answers are grounded in this paper and cite their sources.
Background Neurodevelopmental impairment remains a major long-term complication of maple syrup urine disease (MSUD). Although leucine is a principal neurotoxic metabolite, studies have characterized exposure using clinically distinct measures, including diagnostic or acute peak concentrations and longitudinal indices of metabolic control. We therefore evaluated these exposure patterns separately and examined neurodevelopmental outcomes in the context of early diagnosis and liver transplantation. Methods PubMed/MEDLINE, Scopus, and Web of Science were searched from database inception to July 26, 2026. A total of 203 records were identified through database searching (63 PubMed/MEDLINE, 58 Scopus, and 82 Web of Science); 46 unique studies were included after deduplication, screening, full-text assessment, and supplementary reference-list searching. Leucine exposure was classified as diagnostic/peak or long-term/mean exposure. Quantitative synthesis was restricted to studies with sufficiently comparable populations, exposure definitions, outcomes, and effect measures. Correlations between long-term/mean leucine and IQ were transformed to Fisher's z, pooled using inverse-variance random-effects weighting with the DerSimonian-Laird estimator of between-study variance, and back-transformed to Pearson's r. Heterogeneous outcomes were synthesized narratively. Methodological quality and risk of bias were appraised with JBI tools appropriate to study design. Results Four studies (total N = 61) contributed to the long-term/mean leucine-IQ meta-analysis. Higher long-term/mean leucine exposure was associated with lower IQ (pooled r = −0.40, 95% CI -0.66 to −0.05; I 2 = 39%; tau 2 = 0.056). The 95% prediction interval was −0.77 to 0.17. Leave-one-out analyses identified the small le Roux study as influential; its exclusion yielded r = −0.52 (95% CI −0.70 to −0.27; I 2 = 0%). Diagnostic/peak leucine showed a less consistent relationship with later neurodevelopment and was not combined in a single pool. The approximately 200 μmol/L value reported in longitudinal evidence is best interpreted as a study-level treatment-associated target in young children, not a universal neurotoxicity threshold. Newborn screening and early diagnosis were generally associated with more favorable clinical and neurological outcomes. Liver transplantation consistently improved metabolic stability, whereas neurocognitive improvement was variable. Conclusions Longitudinal leucine exposure appears more consistently associated with neurodevelopmental outcome in MSUD than a single concentration measured at diagnosis or during an acute episode. The findings support early diagnosis and sustained metabolic control while cautioning against interpreting any single leucine value as a universal neurotoxicity threshold. Liver transplantation provides robust metabolic stabilization but may not reverse established cognitive impairment.
No takes yet. Share an insight, caveat, or question.
Dalili et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: